SEMAGLUTIDE
Exceptional evidence quality with consistent results across diverse populations and multiple large trials. The gold standard for peptide weight loss research.
Metabolic researchers studying obesity interventions, endocrinologists investigating diabetes treatments, and pharmaceutical scientists developing next-generation GLP-1 therapies.
Since Jun 2021
30 total, 29 human
#4 most researched
What is SEMAGLUTIDE?
Originally developed for type 2 diabetes, this GLP-1 receptor agonist became the first peptide medication to demonstrate substantial weight loss in large-scale clinical trials. Recent compounding restrictions following FDA shortage resolutions have shifted research focus toward understanding its broader metabolic effects and optimizing treatment protocols.
Semaglutide mimics the incretin hormone GLP-1, binding to receptors in the brain, pancreas, and digestive system. This creates a cascade of effects: the brain receives stronger satiety signals (making you feel full sooner), the stomach empties more slowly (extending that full feeling), and the pancreas releases insulin more efficiently when blood sugar rises.
What the Research Shows
Robust dataset with 27 randomized controlled trials encompassing thousands of participants across obesity, diabetes, and liver disease populations.
Thirty human studies including 27 randomized controlled trials demonstrated that semaglutide 2.4 mg produces clinically significant weight loss across multiple populations, with reductions of 14.9% versus 2.4% placebo in obesity, 15.8% versus 6.4% with liraglutide, and 9.6% versus 3.4% placebo in type 2 diabetes, while also resolving steatohepatitis without fibrosis worsening in 62.9% of patients versus 34.3% with placebo. Continued semaglutide treatment sustained weight loss at 7.9% below baseline compared to 6.9% weight gain after discontinuation.
Notable Studies
Lincoff AM, Brown-Frandsen K, Colhoun HM et al. · N Engl J Med (2023)
RCT · Phase 3 · n=17,60439.8 months
McGuire DK, Marx N, Mulvagh SL et al. · N Engl J Med (2025)
RCT · Phase 3 · n=9,65049.5 months
McGuire DK, Busui RP, Deanfield J et al. · Diabetes Obes Metab (2023)
RCT · Phase 3 · n=9,650
Perkovic V, Tuttle KR, Rossing P et al. · N Engl J Med (2024)
RCT · Phase 3 · n=3,5333.4 years
Garvey WT, Blüher M, Osorto Contreras CK et al. · N Engl J Med (2025)
RCT · Phase 3 · n=3,4176 · 8 weeks
Reported Benefits
Combinations & Interactions
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.